ClinicalTrials.gg
CompletedNCT03672747Updated Jul 31, 2024Results posted

Modulation of Spontaneous Cortical Activity by tDCS: BRAIN Initiative I

An interventional study of transcranial direct-current stimulation (tDCS) in Brain Function, sponsored by University of Nebraska. Completed at 1 site in United States. Open to participants aged 19 Years to 72 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-31.

Sponsored by University of Nebraska · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
19 Years to 72 Years
Sex
All
01

Study summary

This study will determine whether transcranial direct current stimulation (tDCS) can be used alter the amplitude of spontaneous neural activity, and thereby modulate cognitive function in healthy adults

Read the detailed description

An emerging neurological tool, called transcranial Direct Current Stimulation (tDCS), has recently been shown to safely and effectively enhance cognition in healthy individuals, as well as reduce key symptomatology in disorders such as stroke and depression, with only negligible side effects. tDCS delivers low-amplitude current to the scalp using small electrodes and part of this current passes through the skull and modulates neural activity in the underlying brain region. How this tiny amount of electric current acts to improve cognitive function and reduce symptoms (e.g., motor impairments in stroke patients with a lesion in motor brain areas) is currently unknown, although many investigators across the world are now working on this problem. Magnetoencephalography (MEG) offers a unique view of neural function, as it can delineate changes in active brain regions with excellent temporal resolution (\< 1 ms) and high spatial accuracy (2-3 mm). MEG non-invasively measures the magnetic fields that emanate from active neocortical cells. The potential of the MEG technique to precisely monitor the neural effects of tDCS shows extreme promise, but to date the method has been rarely utilized in this area.

Under this protocol, Modulation of Spontaneous Cortical Activity by tDCS: BRAIN Initiative I, approximately 124 participants will provide written informed consent, undergo cognitive and behavioral testing and a structural MRI during a single visit, and then return several weeks later (2-4 weeks) to complete a short tDCS session followed by a MEG recording (i.e., after tDCS). Most participants will return for two more visits, each separated by 2-4 weeks, that include a tDCS session followed by a MEG recording (i.e., 4 total visits). The three tDCS-MEG visits will be identical except that the nature of the stimulation (e.g., location, amplitude, direction/polarity) will be different.

02

Conditions studied

  • Brain Function
03

In context

Lead sponsor

University of Nebraska is the lead sponsor of 495 studies on the registry; 68 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 52 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 72 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Informed consent obtained from the participant.
  • Age: 19-35 years of age at enrollment or 55-72 years of age at enrollment.
  • Gender: males and females included.
  • Right-handed based on the Edinburgh Handedness Inventory
  • Cognitive functioning: Intelligent Quotient (IQ) of 85 - 115 on the Wechsler Adult Intelligence Scale-Revised
  • Ability to complete the questionnaires in English, as not all the neuropsychological tests and questionnaires have been validated in other languages.

Exclusion criteria

Exclusion Criteria:

  • Current use of the following medications: psychotropic medications or other medications with significant CNS effects (e.g., antipsychotics, psychostimulants, anticonvulsants, alpha-agonists, adrenergic blockers, lithium, and sedating antihistamines), or other excluded medication.
  • Current psychiatric diagnosis based on the Mini-International Neuropsychiatric Interview (MINI) and/or the adult attention-deficit/hyperactivity disorder (ADHD) diagnostic interview.
  • Current substance abuse or substance dependence at any time.
  • The presence of a known neurological disorder or any major medical illness or injury impacting neurological/psychiatric function (e.g., diabetes, epilepsy, cerebral palsy, traumatic brain injury, significant environmental/toxic injury, neurodegenerative disorder, past meningitis/encephalitis).
  • General medical conditions: any major medical conditions that would interfere with involvement in the study or may affect central nervous system (CNS) function as judged by the investigative team.
  • History of clinically-significant head trauma.
  • Pregnancy
  • Any other condition that, in the opinion of the investigator, is a contraindication to participation
  • The presence of any ferrous metal implant, including orthodontics (e.g., braces), which may interfere with the MEG data acquisition and/or be a MRI safety concern.
  • Inability to correct visual acuity to 20/20 with corrective lenses (we can correct from +5 to -6 diopters in .5 diopter steps, separately for each eye, with non-magnetic corrective lenses in the laboratory).
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
133 participants (actual)

Study arms

  • Active comparator
    Anodal Brain Stimulation

    Participants will receive anodal stimulation using high-definition tDCS

    Device: transcranial direct-current stimulation (tDCS)

  • Active comparator
    Cathodal Brain Stimulation

    Participants will receive cathodal stimulation using high-definition tDCS

    Device: transcranial direct-current stimulation (tDCS)

  • Sham comparator
    Sham Brain Stimulation (Placebo)

    Participants will receive sham stimulation (placebo) using high-definition tDCS

    Device: transcranial direct-current stimulation (tDCS)

Interventions

  • Devicetranscranial direct-current stimulation (tDCS)

    20 minutes duration using high-definition system with center-surround configuration

    Also known as: Transcranial electrical stimulation

06

What researchers measure

Primary outcomes

  1. Behavioral Performance (Accuracy) on Cognitive Tests of Perceptual Processing

    Do participants perform better in terms of accuracy following tDCS on behavioral measures of perceptual processing.

    Time frame: During the 90 minutes following stimulation

  2. Behavioral Performance (Reaction Time) on Cognitive Tests of Perceptual Processing

    Do participants perform better in terms of reaction time following tDCS on behavioral measures of perceptual processing.

    Time frame: During the 90 minutes following stimulation

Secondary outcomes

  1. The Power of Spontaneous Alpha Activity as Quantified by MEG Imaging

    Does spontaneous alpha (9-13 Hz) power, as measured by MEG, get stronger following tDCS. Spontaneous activity refers to the level of background neural activity and is typically divided into frequency bands (e.g., alpha, gamma) that reflect the number of cycles per second. The outcome measure unit is nano-amperes square (nA\^2) since source-resolved MEG measures reflect electric current strength and not voltage units as in electroencephalography (EEG). The square is necessary since we examined power, which is the square of amplitude in the frequency domain. The unit is also commonly expressed as nAm\^2 since the strength of the electric current is over a defined length.

    Time frame: During the 90 minutes following stimulation

  2. The Power of Oscillatory Alpha Activity as Quantified by MEG Imaging

    Does oscillatory alpha neural activity, as measured by MEG, get stronger following tDCS. Oscillatory activity refers band-limited increases or decreases in the power of neural activity, relative to baseline, in response to a stimulus.

    Time frame: During the 90 minutes following stimulation

  3. The Power of Spontaneous Gamma Activity as Quantified by MEG Imaging

    Does spontaneous gamma (45-80 Hz) power, as measured by MEG, get stronger following tDCS. Spontaneous activity refers to the level of background neural activity and is typically divided into frequency bands (e.g., alpha, gamma) that reflect the number of cycles per second. The outcome measure unit is nano-amperes square (nA\^2) since source-resolved MEG measures reflect electric current strength and not voltage units as in electroencephalography (EEG). The square is necessary since we examined power, which is the square of amplitude in the frequency domain. The unit is also commonly expressed as nAm\^2 since the strength of the electric current is over a defined length.

    Time frame: During the 90 minutes following stimulation

  4. The Power of Oscillatory Gamma Activity as Quantified by MEG Imaging

    Does oscillatory gamma neural activity, as measured by MEG, get stronger following tDCS. Oscillatory activity refers band-limited increases or decreases in the power of neural activity, relative to baseline, in response to a stimulus.

    Time frame: During the 90 minutes following stimulation

07

Results

Posted Jul 31, 2024
Limitations and caveats
Focus on single stimulation amplitude and duration.

Participant flow

Participant flow — Overall Study
MilestoneAnodal Stimulation, Then Cathodal Stimulation, Then ShamAnodal Stimulation, Then Sham Stimulation, Then Cathodal StimulationCathodal Stimulation, Then Anodal Stimulation, Then ShamCathodal Stimulation, Then Sham, Then Anodal StimulationSham Stimulation, Then Anodal Stimulation, Then Cathodal StimulationSham Stimulation, Then Cathodal Stimulation, Then Anodal Stimulation
Started222222232222
Completed212120212021
Not completed112221
Withdrew: Lost to follow-up112221

Outcome measures

PrimaryBehavioral Performance (Accuracy) on Cognitive Tests of Perceptual Processing

Do participants perform better in terms of accuracy following tDCS on behavioral measures of perceptual processing.

Time frame:
During the 90 minutes following stimulation
Reported as:
Mean · percent correct
Behavioral Performance (Accuracy) on Cognitive Tests of Perceptual Processing
percent correctAnodal StimulationCathodal StimulationSham Stimulation (Placebo)
Behavioral Performance (Accuracy) on Cognitive Tests of Perceptual Processing97 ± 1.2698 ± 1.0598 ± .94
SecondaryThe Power of Spontaneous Alpha Activity as Quantified by MEG Imaging

Does spontaneous alpha (9-13 Hz) power, as measured by MEG, get stronger following tDCS. Spontaneous activity refers to the level of background neural activity and is typically divided into frequency bands (e.g., alpha, gamma) that reflect the number of cycles per second. The outcome measure unit is nano-amperes square (nA\^2) since source-resolved MEG measures reflect electric current strength and not voltage units as in electroencephalography (EEG). The square is necessary since we examined power, which is the square of amplitude in the frequency domain. The unit is also commonly expressed as nAm\^2 since the strength of the electric current is over a defined length.

Time frame:
During the 90 minutes following stimulation
Reported as:
Mean · nano-amperes square (nA^2)
The Power of Spontaneous Alpha Activity as Quantified by MEG Imaging
nano-amperes square (nA^2)Anodal StimulationCathodal StimulationSham Stimulation (Placebo)
The Power of Spontaneous Alpha Activity as Quantified by MEG Imaging23.26 ± 3.0615.88 ± 2.1817.02 ± 2.46
SecondaryThe Power of Oscillatory Alpha Activity as Quantified by MEG Imaging

Does oscillatory alpha neural activity, as measured by MEG, get stronger following tDCS. Oscillatory activity refers band-limited increases or decreases in the power of neural activity, relative to baseline, in response to a stimulus.

Time frame:
During the 90 minutes following stimulation
Reported as:
Mean · percent increase/decrease from baseline
The Power of Oscillatory Alpha Activity as Quantified by MEG Imaging
percent increase/decrease from baselineAnodal StimulationCathodal StimulationSham Stimulation (Placebo)
The Power of Oscillatory Alpha Activity as Quantified by MEG Imaging-27.34 ± 3.18-26.10 ± 3.03-30.88 ± 5.11
PrimaryBehavioral Performance (Reaction Time) on Cognitive Tests of Perceptual Processing

Do participants perform better in terms of reaction time following tDCS on behavioral measures of perceptual processing.

Time frame:
During the 90 minutes following stimulation
Reported as:
Mean · milliseconds
Behavioral Performance (Reaction Time) on Cognitive Tests of Perceptual Processing
millisecondsAnodal StimulationCathodal StimulationSham Stimulation (Placebo)
Behavioral Performance (Reaction Time) on Cognitive Tests of Perceptual Processing713 ± 67708 ± 58724 ± 52
SecondaryThe Power of Spontaneous Gamma Activity as Quantified by MEG Imaging

Does spontaneous gamma (45-80 Hz) power, as measured by MEG, get stronger following tDCS. Spontaneous activity refers to the level of background neural activity and is typically divided into frequency bands (e.g., alpha, gamma) that reflect the number of cycles per second. The outcome measure unit is nano-amperes square (nA\^2) since source-resolved MEG measures reflect electric current strength and not voltage units as in electroencephalography (EEG). The square is necessary since we examined power, which is the square of amplitude in the frequency domain. The unit is also commonly expressed as nAm\^2 since the strength of the electric current is over a defined length.

Time frame:
During the 90 minutes following stimulation
Reported as:
Mean · nano-amperes square (nA^2)
The Power of Spontaneous Gamma Activity as Quantified by MEG Imaging
nano-amperes square (nA^2)Anodal StimulationCathodal StimulationSham Stimulation (Placebo)
The Power of Spontaneous Gamma Activity as Quantified by MEG Imaging3.46 ± 1.743.30 ± 1.892.43 ± 1.55
SecondaryThe Power of Oscillatory Gamma Activity as Quantified by MEG Imaging

Does oscillatory gamma neural activity, as measured by MEG, get stronger following tDCS. Oscillatory activity refers band-limited increases or decreases in the power of neural activity, relative to baseline, in response to a stimulus.

Time frame:
During the 90 minutes following stimulation
Reported as:
Mean · percent increase/decrease from baseline
The Power of Oscillatory Gamma Activity as Quantified by MEG Imaging
percent increase/decrease from baselineAnodal StimulationCathodal StimulationSham Stimulation (Placebo)
The Power of Oscillatory Gamma Activity as Quantified by MEG Imaging10.78 ± 2.746.35 ± 1.986.28 ± 1.87

Adverse events

Collected over Each participant was in the study for about one month (4 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anodal Stimulation0/133 (0%)0/133 (0%)0/133 (0%)
Cathodal Stimulation0/133 (0%)0/133 (0%)0/133 (0%)
Sham Stimulation (Placebo)0/133 (0%)0/133 (0%)0/133 (0%)

Baseline characteristics

Of the 133 enrolled, 124 participants completed all interventions. The order of interventions was balanced and the goal was to identify the impact of the intervention and eliminate any effect of administration order.

Age, Categorical
Age, Categorical(Participants)All Study Participants
<=18 years0
Between 18 and 65 years103
>=65 years21
Age, Continuous
Age, Continuous(years)All Study Participants
Mean44 (20 to 72)
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female65
Male59
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Study Participants
Hispanic or Latino14
Not Hispanic or Latino110
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Study Participants
American Indian or Alaska Native0
Asian12
Native Hawaiian or Other Pacific Islander0
Black or African American8
White101
More than one race3
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)All Study Participants
United States124
Mental health questionnaire
Mental health questionnaire(Participants)All Study Participants
Count of participants124
08

Study locations

1 site
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Apr 21, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Upon completion of the study, de-identified data from this study will be stored in the National Institute of Mental Health's (NIMH) Data Archive.

Supporting information: Study protocol

Time frame: Data will be fully updated by the end of the study and will remain publicly available indefinitely.

Access criteria: Approval/Account from the NIMH

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Oct 2022, 43 months.

Results were first posted in Jul 2024, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2018
First posted
Sep 14, 2018
StartActual
Feb 20, 2019
Primary completionActual
Oct 14, 2022
CompletionActual
May 31, 2023
Results first posted
Jul 31, 2024
Last update
Jul 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03672747
Responsible party
Sponsor
First posted
Sep 14, 2018
Start date
Feb 20, 2019
Primary completion
Oct 14, 2022
Completion
May 31, 2023
Results posted
Jul 31, 2024
Last update
Jul 31, 2024

Study contacts

Tony W Wilson, PhD
principal investigator · University of Nebraska

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion